Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19086932 | 0.84 | MAPT (0.45) | KDM4EMAPTALDH1A1TSHRHTT | |
| SCHEMBL3829511 | 0.84 | ALDH1A1 (0.65) | KDM4EMAPTALDH1A1TSHRHTT | |
| SCHEMBL3160394 | 0.84 | MAPT (0.45) | KDM4EMAPTALDH1A1HTTNPSR1 | |
| SCHEMBL23429155 | 0.83 | F10 (0.53) | KDM4EADORA2AMAPTALDH1A1TSHR | |
| SCHEMBL7214056 | 0.82 | KDM4E (0.43) | KDM4EMAPTALDH1A1TSHRHTT | |
| SCHEMBL27500740 | 0.82 | ALDH1A1 (0.43) | KDM4EADORA2AMAPTALDH1A1TSHR | |
| SCHEMBL378335 | 0.81 | SLC34A1 (0.57) | KDM4EMAPTALDH1A1SLC34A1NPSR1 | |
| SCHEMBL18605130 | 0.81 | ALDH1A1 (0.42) | KDM4EADORA2AMAPTALDH1A1TSHR | |
| SCHEMBL31067528 | 0.81 | SCN9A (0.44) | KDM4EMAPTALDH1A1TSHRHTT | |
| SCHEMBL18622979 | 0.81 | NOTUM (0.48) | KDM4EADORA2AMAPTALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708332-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708333-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11685721-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | ITGB1, ITGAV, ITGA1 | KDM4E 2130/4885ADORA2A 705/4885MAPT 4388/4885 |
| US-11708332-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KDM4E 1055/4885ADORA2A 4105/4885MAPT 3007/4885 |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | KDM4E 1757/4885ADORA2A 4318/4885MAPT 2830/4885 |
| US-11708333-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KDM4E 1688/4885ADORA2A 4552/4885MAPT 2685/4885 |
| US-11685721-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KDM4E 954/4885ADORA2A 4290/4885MAPT 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.